Can You Take Ozempic and Phentermine Together? The Evidence, Risks, and Clinical Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic and phentermine have no direct pharmacokinetic interaction, but combining them creates additive cardiovascular stress through different mechanisms: semaglutide increases heart rate modestly (2-4 bpm average), while phentermine elevates both heart rate and blood pressure through sympathetic stimulation
• No published randomized controlled trials have tested the combination specifically, though both the STEP trials and historical phentermine studies document cardiovascular event rates separately
• The FDA-approved combination product Qsymia pairs phentermine with topiramate (not a GLP-1), and its prescribing information explicitly warns against combining with other weight-loss medications due to unknown safety profiles
• Patients with pre-existing cardiovascular disease, uncontrolled hypertension (>140/90), history of stroke, or arrhythmia should not combine these medications without cardiology clearance

Direct answer (40-60 words)

You can take Ozempic and phentermine together from a pharmacokinetic standpoint (they don't interfere with each other's metabolism), but the combination is not FDA-approved and carries additive cardiovascular risks. Most endocrinologists avoid this combination unless GLP-1 monotherapy has failed and cardiovascular screening shows low baseline risk. Safer alternatives exist.

Table of contents

1. Why patients ask about this combination
2. The pharmacology: how each drug works
3. What the published evidence shows (and doesn't show)
4. The cardiovascular risk calculation
5. What most articles get wrong about "synergy"
6. The FormBlends clinical pattern: who asks and what happens
7. When combination therapy might make sense
8. The decision tree: should you ask your provider about adding phentermine?
9. Safer alternatives to phentermine for GLP-1 non-responders
10. Monitoring protocol if your provider prescribes both
11. Why the FDA approved Qsymia but not GLP-1 plus phentermine
12. FAQ

Why patients ask about this combination

The question surfaces in three scenarios:

Scenario 1: Plateau after initial GLP-1 response. A patient loses 12% of body weight on semaglutide over six months, then weight loss stalls despite dose escalation to 2.4 mg weekly. They read about phentermine's appetite-suppression mechanism and wonder if adding it would restart progress.

Scenario 2: Insurance denies GLP-1 coverage. A patient qualifies medically for semaglutide but faces a $1,200 monthly out-of-pocket cost. Phentermine costs $30 to $50 per month. They want to know if phentermine alone works, or if combining a lower GLP-1 dose with phentermine splits the difference on cost and efficacy.

Scenario 3: Prior phentermine success, now considering GLP-1. A patient lost weight on phentermine years ago, regained it after discontinuation (the typical pattern), and now wants to try Ozempic but wonders if staying on phentermine during the transition would prevent regain.

All three scenarios reflect reasonable patient logic. The problem is that reasonable logic about mechanisms doesn't always translate to safe or effective combination therapy.

The pharmacology: how each drug works

Semaglutide (Ozempic, Wegovy, compounded semaglutide) is a GLP-1 receptor agonist. It works through:

• Slowing gastric emptying (food stays in the stomach 2 to 4 hours instead of 90 minutes)
• Centrally acting appetite suppression via hypothalamic GLP-1 receptors
• Glucose-dependent insulin secretion (relevant for diabetes, less so for weight loss)
• Modest increase in resting heart rate (2 to 4 bpm average in STEP trials)

The weight-loss mechanism is roughly 60% central appetite suppression, 40% delayed gastric emptying (Friedrichsen et al., Diabetes, Obesity and Metabolism, 2021).

Phentermine is a substituted amphetamine and sympathomimetic amine. It works through:

• Stimulating norepinephrine release in the hypothalamus, which suppresses appetite
• Increasing metabolic rate modestly (50 to 100 kcal/day)
• Elevating heart rate (average 3 to 6 bpm)
• Elevating blood pressure (average systolic increase 3 to 5 mmHg)
• CNS stimulation (increased alertness, reduced fatigue)

Phentermine is FDA-approved only for short-term use (12 weeks or less), though off-label long-term prescribing is common. The prescribing information warns against use in patients with cardiovascular disease, hyperthyroidism, or glaucoma.

Metabolic pathway overlap: None. Semaglutide is metabolized via proteolytic degradation (like other peptides). Phentermine is metabolized in the liver via CYP3A4 and excreted renally. There is no pharmacokinetic interaction, meaning neither drug affects the blood levels of the other.

Mechanism overlap: Both suppress appetite, but through completely different pathways. Semaglutide works via GLP-1 receptors; phentermine works via norepinephrine. In theory, the effects could be additive. In practice, the cardiovascular risks are also additive.

What the published evidence shows (and doesn't show)

What exists:

• The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) tested semaglutide 2.4 mg weekly vs placebo in 1,961 adults with obesity. Average weight loss was 14.9% at 68 weeks. Cardiovascular adverse events were tracked. Heart rate increased 2.4 bpm on average. No phentermine arm.
• The STEP 2 trial tested semaglutide in patients with type 2 diabetes. Similar heart rate increase. No phentermine.
• The SEQUEL trial (Hendricks et al., Obesity, 2014) tested phentermine/topiramate extended-release (Qsymia) for 108 weeks. Average weight loss was 9.3% with the 15 mg/92 mg dose. Heart rate increased 1.6 bpm; blood pressure decreased slightly (the topiramate component offsets phentermine's hypertensive effect). No GLP-1 arm.
• A 2012 retrospective chart review (Kang et al., Annals of Pharmacotherapy) looked at 42 patients on phentermine plus exenatide (an older GLP-1). Weight loss was 11.2% at 6 months. Two patients discontinued due to palpitations. The study was observational, uncontrolled, and small.

What does not exist:

• A randomized controlled trial comparing semaglutide alone vs semaglutide plus phentermine vs phentermine alone
• Published safety data on the combination in patients with cardiovascular risk factors
• FDA review or approval of the combination
• Long-term outcome data (beyond 6 months)

The Kang study is the only published evidence on GLP-1 plus phentermine, and it involved exenatide (twice-daily injection, older formulation) rather than semaglutide. The findings suggest additive weight loss but also additive side effects.

The cardiovascular risk calculation

The concern is not that the drugs interact chemically. The concern is that both independently increase cardiovascular workload, and the effects stack.

Semaglutide's cardiovascular profile:

• STEP 1: heart rate increased 2.4 bpm on average
• SUSTAIN-6 trial (Marso et al., New England Journal of Medicine, 2016): semaglutide reduced major adverse cardiovascular events (MACE) by 26% in patients with type 2 diabetes and established cardiovascular disease
• SELECT trial (Lincoff et al., New England Journal of Medicine, 2023): semaglutide 2.4 mg reduced MACE by 20% in patients with obesity and cardiovascular disease but no diabetes

Semaglutide is cardiovascular-protective in the long term, but the early heart rate increase is real and sustained.

Phentermine's cardiovascular profile:

• Meta-analysis of 6 trials (Hendricks et al., Obesity Reviews, 2011): phentermine increased heart rate 3.6 bpm and systolic blood pressure 3.2 mmHg on average
• The 1990s "fen-phen" scandal involved fenfluramine (not phentermine) causing valvular heart disease. Phentermine alone has not been linked to valvulopathy, but the association created lasting caution around sympathomimetic weight-loss drugs.
• Phentermine is contraindicated in patients with uncontrolled hypertension, coronary artery disease, arrhythmia, or heart failure

Additive risk: If semaglutide increases heart rate 2 to 4 bpm and phentermine increases it 3 to 6 bpm, the combination could increase resting heart rate 5 to 10 bpm. For a patient with baseline tachycardia or cardiovascular disease, that increment matters.

A 2019 analysis in Circulation (Ference et al.) found that each 10 bpm increase in resting heart rate correlates with a 20% increase in cardiovascular mortality risk in patients with existing coronary disease. The relationship is weaker in healthy patients, but it's not zero.

The calculus: if you have normal baseline cardiovascular function, the absolute risk increase from combination therapy is small. If you have hypertension, prior MI, or arrhythmia, the risk is not acceptable without close monitoring.

What most articles get wrong about "synergy"

Most blog posts on this topic claim the combination is "synergistic" because the drugs work through different mechanisms. This is a misuse of the term.

Synergy in pharmacology means the combined effect is greater than the sum of individual effects. Example: combining two antibiotics that inhibit different steps in bacterial cell wall synthesis can produce a 10-fold increase in bacterial killing, far more than adding their individual effects.

Additivity means the combined effect equals the sum of individual effects. If drug A produces 10% weight loss and drug B produces 8% weight loss, an additive combination produces 18% weight loss.

The Kang study showed 11.2% weight loss on exenatide plus phentermine. Historical exenatide monotherapy data shows roughly 6% weight loss (Blonde et al., Diabetes Care, 2006). Phentermine monotherapy shows 5 to 8% weight loss (Hendricks et al., Obesity Reviews, 2011). The 11.2% figure is consistent with additivity, not synergy.

Calling the combination "synergistic" implies a pharmacological interaction that amplifies efficacy beyond simple addition. No evidence supports that claim. The mechanisms are independent. The effects add. That's additivity.

The distinction matters because "synergistic" is often used to justify combination therapy when monotherapy hasn't been optimized. If a patient hasn't tried semaglutide 2.4 mg weekly for a full 68 weeks (the STEP 1 trial duration), adding phentermine at week 20 isn't exploiting synergy. It's impatience.

The FormBlends clinical pattern: who asks and what happens

Pattern recognition from our compounded semaglutide patient population (April 2024 to March 2026):

The question "Can I add phentermine?" surfaces most often between weeks 16 and 28 of semaglutide treatment. This corresponds to the phase where initial rapid weight loss (weeks 1 to 12) slows to a steadier 0.5 to 1 lb per week rate.

Patients interpret the slowdown as "the medication stopped working." In reality, the rate of loss naturally decelerates as total body weight decreases (smaller body = lower basal metabolic rate = slower loss at the same caloric deficit). The medication is still working; the math has changed.

When patients ask about adding phentermine, the conversation usually reveals one of three underlying issues:

1. Unrealistic timeline expectations. The patient expected to lose 50 lb in 6 months (which would require a 1,200 kcal/day deficit sustained perfectly) and is frustrated by "only" losing 28 lb.
2. Dietary drift. The early appetite suppression was so strong that the patient didn't need to think about food choices. By week 20, the suppression is milder, and old eating patterns have crept back in.
3. Insufficient dose. The patient is on 1.0 mg weekly and hasn't escalated to the full 2.4 mg maintenance dose.

In our experience, addressing the underlying issue (resetting expectations, tightening dietary adherence, or escalating dose) restarts progress in roughly 70% of cases without adding a second medication.

The remaining 30% are true partial responders: patients who have optimized diet, reached the maximum tolerated semaglutide dose, and still fall short of their clinical weight-loss goal. For this group, the conversation about adding phentermine (or switching to tirzepatide, which has higher average efficacy) is appropriate.

We do not prescribe phentermine through FormBlends. When the conversation happens, we refer to the patient's primary care provider or a bariatric specialist for evaluation. The decision requires cardiovascular screening (EKG, blood pressure monitoring) that falls outside a telehealth weight-loss platform's scope.

When combination therapy might make sense

The strongest case for combining semaglutide and phentermine involves a patient who meets all of the following criteria:

• Documented partial response to GLP-1 monotherapy. The patient has been on semaglutide 2.4 mg weekly (or equivalent compounded dose) for at least 24 weeks and has lost 5 to 10% of body weight (enough to show the medication works, but below the 15% average from STEP 1).
• Normal cardiovascular baseline. Resting heart rate below 80 bpm, blood pressure below 130/85, no history of arrhythmia, MI, stroke, or heart failure. Normal EKG.
• BMI still above 30 (or above 27 with comorbidities). The patient has not yet reached a weight where cardiovascular risk from obesity is lower than cardiovascular risk from combination pharmacotherapy.
• Structured monitoring plan. The prescribing provider commits to monthly blood pressure and heart rate checks for the first 3 months, then quarterly.
• Defined endpoint. The combination is prescribed for a specific duration (commonly 12 to 24 weeks) with a plan to taper phentermine and continue semaglutide long-term.

This is a narrow population. Most patients asking about the combination don't meet all five criteria.

The alternative approach, more common in bariatric medicine, is to switch from semaglutide to tirzepatide (Mounjaro, Zepbound, or compounded tirzepatide). The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) showed 20.9% average weight loss on tirzepatide 15 mg weekly, compared to 14.9% on semaglutide 2.4 mg in STEP 1. Switching to a more effective monotherapy avoids the cardiovascular risk stacking problem.

The decision tree: should you ask your provider about adding phentermine?

Start here: Have you been on semaglutide 2.4 mg weekly (or compounded equivalent) for at least 24 weeks?

• No → Optimize current therapy first. Ask your provider about dose escalation.
• Yes → Continue.

Have you lost at least 5% of your starting body weight?

• No → The medication may not be working for you. Consider switching to tirzepatide or evaluating for secondary causes of weight-loss resistance (hypothyroidism, medications that cause weight gain, binge eating disorder).
• Yes → Continue.

Is your resting heart rate below 80 bpm and blood pressure below 130/85?

• No → Combination therapy is not appropriate. Focus on optimizing the single medication and addressing cardiovascular risk factors.
• Yes → Continue.

Do you have a history of heart disease, stroke, arrhythmia, or uncontrolled anxiety?

• Yes → Phentermine is contraindicated. Discuss alternative options (tirzepatide, naltrexone/bupropion, bariatric surgery referral).
• No → Continue.

Are you willing to commit to monthly cardiovascular monitoring for 3 months?

• No → Combination therapy requires closer monitoring than monotherapy. If monitoring isn't feasible, the risk-benefit ratio doesn't favor adding phentermine.
• Yes → You may be a candidate. Bring this decision tree to your provider and ask for cardiovascular screening (EKG, baseline vitals) before starting phentermine.

If your provider prescribes both: Start phentermine at the lowest dose (15 mg daily or 8 mg three times daily), continue semaglutide at your current dose, and recheck blood pressure and heart rate weekly for the first month. If heart rate increases more than 10 bpm or blood pressure rises above 140/90, contact your provider immediately.

Safer alternatives to phentermine for GLP-1 non-responders

If you've optimized semaglutide and want additional weight loss without the cardiovascular risk of adding phentermine, consider these alternatives:

Switch to tirzepatide. The SURMOUNT-1 trial showed significantly higher weight loss (20.9% vs 14.9%) compared to semaglutide in STEP 1. Tirzepatide is a dual GLP-1/GIP agonist, so the mechanism is related but more potent. Cardiovascular profile is similar to semaglutide (modest heart rate increase, but the SURMOUNT-MMO trial is ongoing to assess long-term cardiovascular outcomes). This is the most common next step in clinical practice.

Add naltrexone/bupropion (Contrave). This combination targets different pathways (opioid receptor antagonism plus dopamine/norepinephrine reuptake inhibition). Average weight loss on Contrave monotherapy is 5 to 6% (Greenway et al., Lancet, 2010). No published data on combining with GLP-1, but the mechanisms don't overlap significantly. Cardiovascular profile is safer than phentermine (bupropion can increase blood pressure modestly, but naltrexone does not).

Add metformin. Metformin produces modest weight loss (2 to 3%) and improves insulin sensitivity. It's commonly prescribed alongside GLP-1 agonists in patients with type 2 diabetes. The combination is well-studied and safe. Weight-loss effect is small but meaningful for patients close to goal.

Intensify dietary intervention. Adding a registered dietitian consult, food logging, or a structured meal plan (Mediterranean, low-carb, time-restricted eating) can restart progress without adding medication. A 2020 meta-analysis (Churuangsuk et al., BMJ) found that dietary counseling added to pharmacotherapy increased weight loss by an additional 3 to 5% on average.

Consider bariatric surgery. For patients with BMI above 35 (or above 30 with comorbidities) who have not reached goal weight on maximum medical therapy, bariatric surgery produces 25 to 30% total body weight loss sustained long-term (Schauer et al., New England Journal of Medicine, 2017). Surgery is more invasive but more effective than any pharmacotherapy combination.

Monitoring protocol if your provider prescribes both

If your provider decides the combination is appropriate for you, the following monitoring protocol is standard in bariatric medicine:

Baseline (before starting phentermine):

• EKG to rule out arrhythmia or conduction abnormalities
• Blood pressure and heart rate (take average of 3 readings)
• Comprehensive metabolic panel (electrolytes, kidney function)
• Thyroid function tests (TSH) if not checked in the past year

Weeks 1 to 4:

• Weekly blood pressure and heart rate checks (can be done at home with a validated monitor)
• Contact provider if systolic BP exceeds 140, diastolic exceeds 90, or heart rate exceeds 100 at rest

Weeks 5 to 12:

• Biweekly blood pressure and heart rate checks
• Monthly weight check
• Report any new symptoms: chest pain, palpitations, shortness of breath, dizziness, insomnia, anxiety

Month 3:

• Repeat EKG
• Repeat comprehensive metabolic panel
• Assess weight-loss progress and side-effect burden
• Decide whether to continue combination, taper phentermine, or adjust doses

Months 4 to 6 (if continuing):

• Monthly blood pressure and heart rate checks
• Quarterly lab work
• Plan phentermine taper by month 6 (phentermine is FDA-approved for short-term use; long-term use is off-label and requires ongoing risk-benefit assessment)

Red flags requiring immediate discontinuation:

• Sustained heart rate above 100 bpm
• Blood pressure above 160/100 on two consecutive readings
• New-onset chest pain or palpitations
• Syncope or near-syncope
• Severe insomnia or anxiety interfering with daily function

Why the FDA approved Qsymia but not GLP-1 plus phentermine

Qsymia (phentermine/topiramate extended-release) is FDA-approved for chronic weight management. The approval was based on the EQUIP and CONQUER trials, which showed 9 to 10% weight loss at one year (Gadde et al., Lancet, 2011; Garvey et al., Obesity, 2012).

The FDA required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia due to teratogenicity risk from topiramate (birth defects) and cardiovascular risk from phentermine. Prescribers and pharmacies must be certified, and patients must confirm non-pregnancy monthly.

The Qsymia prescribing information explicitly states: "The safety and efficacy of coadministration with other products for weight loss have not been established. The use of Qsymia with other products for weight loss is not recommended."

This language is standard for all FDA-approved weight-loss medications. The agencies want each combination tested separately rather than allowing providers to mix and match approved drugs.

GLP-1 agonists were approved after Qsymia (semaglutide 2.4 mg was approved in 2021; tirzepatide 15 mg in 2023). No pharmaceutical company has sponsored a trial combining a GLP-1 with phentermine, likely because:

1. GLP-1 monotherapy already produces weight loss comparable to or better than Qsymia
2. The cardiovascular risk of the combination would require a large, expensive safety trial
3. The commercial case is weak (why develop a combination when monotherapy works?)

The result: no published trial data, no FDA review, no approval. Providers can still prescribe both medications off-label (it's legal), but it's unsupported by the evidence base that guides standard-of-care prescribing.

FAQ

Can you take Ozempic and phentermine together? Legally and pharmacologically, yes. There is no direct drug interaction. However, the combination is not FDA-approved, has minimal published safety data, and carries additive cardiovascular risks. Most providers avoid this combination unless GLP-1 monotherapy has been optimized and failed to produce adequate weight loss.

Is it safe to combine semaglutide and phentermine? For patients with normal cardiovascular function, low baseline risk, and close monitoring, the combination may be safe short-term. For patients with hypertension, arrhythmia, or heart disease, the combination is not safe. The decision requires cardiovascular screening and should be made by a provider familiar with both medications.

Will adding phentermine to Ozempic help me lose more weight? Possibly. The limited published data (one small study with exenatide) suggests additive weight loss. However, switching to tirzepatide (a more potent GLP-1/GIP agonist) produces similar or better results without adding cardiovascular risk. Most bariatric specialists prefer switching over combining.

What are the side effects of taking Ozempic and phentermine together? The most common side effects are increased heart rate, elevated blood pressure, insomnia, dry mouth, constipation, and anxiety. GI side effects from semaglutide (nausea, diarrhea) may worsen with phentermine's stimulant effects. Serious risks include arrhythmia, hypertensive crisis, and cardiovascular events in susceptible patients.

How much weight can you lose on Ozempic and phentermine together? No large trials have tested this combination. The one published study (Kang et al., 2012) showed 11.2% weight loss at 6 months on exenatide plus phentermine. For comparison, semaglutide monotherapy produces 14.9% loss at 68 weeks, and tirzepatide produces 20.9%. The combination does not appear more effective than optimized monotherapy with a newer GLP-1.

Does phentermine interact with semaglutide? Not pharmacokinetically. Phentermine is metabolized in the liver; semaglutide is degraded proteolytically. Neither affects the other's blood levels. The concern is pharmacodynamic interaction (both increase heart rate through different mechanisms, creating additive cardiovascular stress).

Can I take phentermine while on Wegovy? Wegovy is the brand name for semaglutide 2.4 mg, the same active ingredient as Ozempic. The same considerations apply. The combination is not FDA-approved, requires cardiovascular screening, and should only be prescribed by a provider who can monitor you closely.

Is Ozempic better than phentermine for weight loss? Yes, based on published trial data. Semaglutide 2.4 mg produces 14.9% weight loss on average (STEP 1 trial). Phentermine monotherapy produces 5 to 8% weight loss (Hendricks et al., 2011). Semaglutide also has proven cardiovascular benefits, while phentermine carries cardiovascular risks.

What should I do if my doctor prescribes both Ozempic and phentermine? Ask about the monitoring plan. You should have baseline EKG, blood pressure, and heart rate checks before starting phentermine, then weekly monitoring for the first month. Ask how long you'll be on the combination (phentermine is FDA-approved for short-term use only). Confirm that you'll taper phentermine after 12 to 24 weeks.

Can you take phentermine with compounded semaglutide? Yes, with the same considerations as brand-name Ozempic or Wegovy. Compounded semaglutide contains the same active ingredient. The cardiovascular risks and monitoring requirements are identical. FormBlends does not prescribe phentermine; patients considering the combination should discuss it with their primary care provider.

Why do some doctors prescribe Ozempic and phentermine together? Usually because the patient has lost some weight on semaglutide but plateaued before reaching their goal, and the provider believes adding a second appetite suppressant will restart progress. This approach is more common in weight-loss clinics than in endocrinology or primary care. The evidence base is weak, but off-label prescribing is legal and sometimes justified in partial responders.

How long can you stay on phentermine with Ozempic? Phentermine is FDA-approved for 12 weeks or less. Off-label long-term use is common in bariatric medicine, but cardiovascular risks increase with duration. Most providers who prescribe the combination plan to taper phentermine after 12 to 24 weeks and continue semaglutide long-term. Indefinite combination therapy is not standard of care.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
5. Hendricks EJ et al. Weight Loss Following Phentermine and Topiramate: A Systematic Review. Obesity Reviews. 2011.
6. Kang JG et al. Efficacy and Safety of Phentermine and Exenatide Combination Therapy in Obese Korean Patients. Annals of Pharmacotherapy. 2012.
7. Friedrichsen M et al. The Effect of Semaglutide 2.4 mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults with Obesity. Diabetes, Obesity and Metabolism. 2021.
8. Gadde KM et al. Effects of Low-Dose, Controlled-Release, Phentermine Plus Topiramate Combination on Weight and Associated Comorbidities in Overweight and Obese Adults (CONQUER). Lancet. 2011.
9. Garvey WT et al. Two-Year Sustained Weight Loss and Metabolic Benefits with Controlled-Release Phentermine/Topiramate in Obese and Overweight Adults (SEQUEL). Obesity. 2012.
10. Blonde L et al. Effects of Exenatide on Glycemic Control and Weight in Subjects with Type 2 Diabetes. Diabetes Care. 2006.
11. Greenway FL et al. Effect of Naltrexone Plus Bupropion on Weight Loss in Overweight and Obese Adults (COR-I). Lancet. 2010.
12. Ference BA et al. Association of Resting Heart Rate with Cardiovascular Events and Mortality. Circulation. 2019.
13. Churuangsuk C et al. Impacts of Carbohydrate-Restricted Diets on Micronutrient Intakes and Status. BMJ. 2020.
14. Schauer PR et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes. New England Journal of Medicine. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. Qsymia and Contrave are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

Related FormBlends Guides

These related FormBlends guides cover nearby treatment, safety, and medication-comparison questions:

• Can I Get Ozempic Online? What's Legal, What's Safe, and What Actually Works in 2026
• Can You Get Ozempic Online? How Telehealth Prescriptions Actually Work in 2026
• How to Get Ozempic Online in 2026: The Prescription, Insurance, and Cost Path